Summit Therapeutics (SMMT) Receives New Coverage from Analysts at SunTrust Banks
SunTrust Banks assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMT) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $24.00 price target on the stock.
A number of other equities research analysts have also issued reports on SMMT. HC Wainwright set a $16.00 target price on Summit Therapeutics and gave the stock a buy rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered Summit Therapeutics from a hold rating to a sell rating in a research report on Thursday, December 28th. Oppenheimer reaffirmed a buy rating and set a $24.00 target price on shares of Summit Therapeutics in a research report on Monday, October 16th. Canaccord Genuity reaffirmed a buy rating on shares of Summit Therapeutics in a research report on Monday, October 16th. Finally, ValuEngine lowered Summit Therapeutics from a hold rating to a sell rating in a research report on Thursday, October 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Summit Therapeutics currently has a consensus rating of Buy and an average target price of $21.00.
Shares of Summit Therapeutics (SMMT) traded down $0.19 during trading on Thursday, hitting $11.07. The stock had a trading volume of 32,998 shares, compared to its average volume of 19,805. The firm has a market capitalization of $153.39, a price-to-earnings ratio of -110.70 and a beta of 0.37. Summit Therapeutics has a 12 month low of $8.75 and a 12 month high of $16.86.
About Summit Therapeutics
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.